Is Your Paper Ready for JAMA? Evidence-Based Medicine at Its Most Selective

JAMA's desk rejection rate of approximately 80% means four out of five papers never reach a reviewer. The editorial screening focuses on three dimensions:

Clinical or public health significance at scale. JAMA wants studies whose findings affect how physicians practice or how health systems operate for large patient populations. A trial showing that drug A beats drug B for a common condition clears this bar. A pilot study suggesting that a novel intervention might work in a small subgroup doesn't.

Methodological rigor appropriate to the question. JAMA's editors are evidence-based medicine experts. They'll spot design flaws in the abstract. If you're reporting a treatment comparison without randomization and don't have a compelling justification (natural experiment, regression discontinuity, instrumental variable), the desk rejection will mention study design.

Relevance to JAMA's readership. JAMA's audience is heavily weighted toward US-based physicians, including internists, family medicine physicians, and generalists. Research that's highly specialized or relevant only to non-US health systems may be redirected to a JAMA Network specialty journal or The Lancet.

JAMA uses a structured abstract format that's distinct from NEJM's and The Lancet's. The maximum length is 350 words, and the required headings are:

• Importance: Why this study matters. Not background information, but the specific clinical or public health gap this study addresses.

• Objective: What the study aimed to test or evaluate. One sentence is ideal.

• Design, Setting, and Participants: Study type, where it was done, who was included. Be specific about enrollment dates and eligibility criteria.

• Interventions: What was tested (for intervention studies) or what exposure was examined.

• Main Outcomes and Measures: Primary endpoint and how it was measured.

• Results: Key findings with effect sizes, confidence intervals, and p-values.

• Conclusions and Relevance: What the findings mean for clinical practice or health policy. Not a restatement of results.

JAMA also requires a Key Points box of 75-100 words summarizing the question, findings, and meaning. This is separate from the abstract and appears prominently in the published article. Editors read this during triage, so don't treat it as an afterthought.

The "Importance" heading deserves attention. Most journals start with "Background" or "Context." JAMA's choice of "Importance" is deliberate. They want you to justify why this study needed to be done, not describe what's already known. If your Importance section reads like a literature review, rewrite it.

Papers that clear the desk enter a review process with several distinctive features:

Multiple reviewer types. JAMA typically assigns two to three clinical experts plus, often, a statistical reviewer. For some papers, JAMA also invites a patient or policy reviewer when the study has direct implications for patient care or health systems.

Structured review forms. JAMA reviewers complete detailed forms assessing specific aspects of the paper: importance of the research question, appropriateness of the study design, adequacy of the statistical analysis, clarity of reporting, and clinical significance of the findings. This structured approach means reviews tend to be systematic and thorough.

Reporting guideline enforcement. JAMA strictly enforces CONSORT (RCTs), STROBE (observational), PRISMA (systematic reviews), STARD (diagnostic accuracy), and other reporting guidelines. Incomplete reporting checklists can delay your paper or trigger return for revision before review even begins.

Open data expectations. JAMA has increasingly emphasized data sharing. For clinical trials, you'll be asked to provide a data sharing statement and, in many cases, to make individual participant data available to qualified researchers within a specified timeframe.

JAMA's biggest structural advantage for authors is the JAMA Network, which includes 13 specialty journals:

JAMA Internal Medicine, JAMA Oncology, JAMA Cardiology, JAMA Neurology, JAMA Psychiatry, JAMA Surgery, JAMA Dermatology, JAMA Ophthalmology, JAMA Otolaryngology, JAMA Pediatrics, JAMA Network Open, JAMA Health Forum, and others.

When JAMA rejects a paper, editors can recommend transfer to a specific JAMA Network journal. The reviewer reports travel with the manuscript, which can shorten the review process at the receiving journal significantly. JAMA Network Open, in particular, has become a strong landing spot for methodologically sound papers that don't meet the flagship's significance threshold.

This cascade makes JAMA a reasonable first-attempt journal even for specialty-focused research. If the work is important enough for the specialty audience, the JAMA Network journal may accept it with the benefit of existing reviews. If it's important enough for the general medical audience, JAMA itself will consider it.

These three journals are the pinnacle of general medical publishing, but they have different editorial personalities:

Choose JAMA when your paper addresses a clinical or public health question relevant to a broad physician audience, has strong methodology, and you value the JAMA Network as a backup. JAMA is particularly strong for health disparities research, preventive medicine, and health policy studies that other top journals might not prioritize.

Choose NEJM when your paper is a large clinical trial with hard endpoints that will change treatment guidelines. NEJM's 21-day decision time makes it worth trying first if you think your paper has a shot.

Choose The Lancet when your paper has a global health dimension, especially if it involves research from low- and middle-income countries or has direct health policy implications beyond clinical practice.

A JAMA manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

Before preparing a JAMA submission, ask yourself:

Is this study important enough for a general medical audience? JAMA's readers span all of medicine. If your paper matters only to cardiologists, it belongs in JAMA Cardiology or Circulation. If it matters to all physicians, or to the health system broadly, JAMA is appropriate.

Does the methodology match the question? JAMA's editors are methodological purists. If a randomized trial was feasible and you did an observational study instead, you'll need a strong justification. If you used a novel analytical approach, make sure it's validated.

Have you completed the Key Points box? This 75-100 word summary is required at submission and reviewed during triage. Many authors skip it or write it carelessly. Don't. It's one of the first things editors read.

Is your abstract structured correctly? JAMA's headings (Importance, Objective, Design/Setting/Participants, etc.) are specific. If you're repurposing an abstract written for another journal, adjust the headings and content to match JAMA's format exactly.

Have you attached all reporting checklists? CONSORT, STROBE, PRISMA, or whatever applies to your study design. Missing checklists delay processing and suggest carelessness.

A JAMA submission readiness check can help evaluate whether your manuscript's clinical significance and methodological presentation align with JAMA's specific editorial priorities before you submit.

In our pre-submission review work with manuscripts targeting JAMA, five patterns generate the most consistent desk rejections worth knowing before submission.

Clinical trials testing already-answered questions (roughly 35% of desk rejections in our review work). According to JAMA instructions for authors, the journal prioritizes trials that resolve genuine clinical equipoise. Editors consistently desk-reject trials that are adequately powered but replicate findings from established literature without adding new clinical subgroups, populations, or treatment modifications. In our experience, roughly 35% of trial desk rejections trace to this failure to establish genuine equipoise.

Observational studies that conflate statistical significance with clinical significance (roughly 25%). JAMA editors require that statistically significant associations be placed in context of absolute risk differences and number needed to treat. Editors consistently reject papers that emphasize p-values without addressing clinical magnitude. In our experience, roughly 25% of observational study desk rejections involve this framing failure.

Diagnostic accuracy studies with imperfect or unjustified composite reference standards (roughly 20%). JAMA expects diagnostic papers to address the limitations of the reference standard and the potential for incorporation bias. Editors consistently challenge papers where the reference standard is imperfect but no justification or sensitivity analysis is provided. In our experience, roughly 20% of diagnostic study rejections involve this methodological gap.

Health services research papers without a comparison group or temporal control (roughly 15%). Descriptive analyses of healthcare utilization or outcomes without a counterfactual are treated as insufficient evidence for JAMA's clinical standards. Editors consistently return papers that describe utilization patterns without a comparison group. In our experience, roughly 15% of health services research submissions are returned at the desk for this reason.

Case series submitted as research articles rather than through the JAMA Case Reports pathway (roughly 10%). JAMA distinguishes clinical research articles from case-based learning. Editors consistently redirect case reports submitted to the main journal to the appropriate pathway rather than proceeding with review. In our experience, roughly 10% of case-based submissions are rerouted at the desk without a content decision.

SciRev community data for JAMA confirms the review timeline and rejection patterns documented above.

Before submitting to JAMA, a JAMA manuscript fit check identifies whether your clinical significance framing, methodological approach, and Key Points box meet JAMA's editorial bar before you commit to the submission.

Ready to submit if:

• You can pass every item on this checklist without qualifying language
• An experienced colleague in your field has read the manuscript and agrees it's competitive
• The data package is complete - no pending experiments or analyses
• You have identified why this journal specifically (not just prestige) is the right venue

Not ready yet if:

• You skipped items on this checklist because you "plan to add them later"
• The methods section still has draft or incomplete protocol text
• Key figures are drafts rather than publication-quality
• You cannot articulate what distinguishes this paper from recent publications in this journal

• Manusights local fit and process context from JAMA acceptance rate, JAMA under review, and JAMA Oncology cover letter.

• Clarivate Journal Citation Reports (JCR 2024)